Skip to main content

AIM ImmunoTech Inc.

AIM
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000946644

In the last 90 days, AIM ImmunoTech Inc. insiders filed 4 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $325.6K in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding AIM ImmunoTech Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of AIM: Q3 2023 compared with Q4 2023
MeasureQ3 2023Q4 2023Change
Holders38380
Shares4.33M4.15M−172.3K (−4.0%)
Value$1.97M$1.83M−$140.4K (−7.1%)

New holders (4)

Institutions that held AIM ImmunoTech Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to AIM in Q4 2023
InstitutionSharesValue% of portfolio
Citadel Advisors LLC34,018$15.0K0.00%
Susquehanna International Group, LLP15,201$6.69K0.00%
FMR LLC5$20.00%
BNP Paribas Arbitrage, SA2$10.00%

Sold out (4)

Institutions that held AIM ImmunoTech Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of AIM in Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Two Sigma Securities, LLC60,649$27.6K
HRT Financial LP10,816$4.00K
VisionPoint Advisory Group, LLC3,142$1.43K
IAG Wealth Partners, LLC480$218